Standardized and relevant psoriasis-specific outcome measures would contribute to a better understanding of the benefits of a growing list of highly effective therapies. To this end, in this issue of JAMA Dermatology, Callis Duffin et al1 present the results of an effort to define core outcome sets (COSs) for clinical trials of psoriasis. Under the auspices of the International Dermatology Outcome Measures group, the authors conducted a Delphi survey and determined that the following 6 domains should be addressed in all psoriasis trials: (1) psoriatic skin manifestations (including location), (2) an investigator global assessment, (3) an evaluation of signs and symptoms of both psoriasis and psoriatic arthritis, (4) a patient global assessment of his or her condition, (5) an assessment of treatment satisfaction, and (6) a measure of health-related quality of life.
Strober BE, Gordon KB. Core Outcome Sets for Psoriasis Clinical Trials: Definition, Consensus, and Acceptance. JAMA Dermatol. 2018;154(10):1135. doi:10.1001/jamadermatol.2018.1166
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: